Core Points - The Guangxi Zhuang Autonomous Region's Medical Insurance Bureau has recently implemented a policy to include 75 newly negotiated national drugs in a separate outpatient payment system, expected to increase annual medical insurance fund expenditure by 232 million yuan [1] - This initiative aims to enhance outpatient reimbursement benefits and reduce the medical burden on insured patients, particularly for those with special chronic diseases that lack sufficient coverage [1][2] - The total number of drugs under the separate outpatient payment system has now reached 147, including 44 rare disease medications, benefiting patients with conditions such as multiple sclerosis and hypophosphatemic rickets [3] Summary by Category Policy Implementation - The new policy officially took effect this month, marking the first large-scale expansion of the drug list under the separate outpatient payment system established in June 2022 [1] - The system allows insured individuals to access specific outpatient drugs without a deductible, with reimbursement rates of 50% for resident insurance and 70%-75% for employee insurance, depending on employment status [1] Financial Impact - The policy is projected to increase the medical insurance fund expenditure by 232 million yuan annually [1] - For example, a patient previously faced an annual treatment cost of 52,500 yuan, with only 2,000 yuan reimbursed under standard outpatient coverage, resulting in a personal burden of 50,500 yuan. Under the new system, reimbursement can rise to 36,800 yuan, reducing personal costs to 15,700 yuan, thus increasing the reimbursement rate from 4% to 70% [2] Patient Benefits - The policy significantly alleviates the financial burden on patients and reduces the overall costs associated with hospitalization [2] - As of May 2025, over 174,300 individuals have benefited from the separate outpatient payment system, with the medical insurance fund reimbursing 314 million yuan at an average reimbursement rate of 65.3% [3]